Claims for Patent: 11,357,782
✉ Email this page to a colleague
Summary for Patent: 11,357,782
| Title: | Treprostinil administration by inhalation |
| Abstract: | Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil. |
| Inventor(s): | Horst Olschewski, Robert Roscigno, Lewis J. Rubin, Thomas Schmehl, Werner Seeger, Carl Sterritt, Robert Voswinckel |
| Assignee: | United Therapeutics Corp |
| Application Number: | US17/486,721 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,357,782 |
| Patent Claims: |
1. A method of treating pulmonary hypertension comprising: providing an inhalation device for treating pulmonary hypertension in a human suffering from pulmonary hypertension comprising a powder formulation of treprostinil or a pharmaceutically acceptable salt thereof and a dry powder inhaler configured to administer single event dose of the powder formulation comprising treprostinil or a pharmaceutically acceptable salt thereof, wherein the single event dose comprises at least 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof delivered in 1 to 3 breaths, wherein the dry powder inhaler is configured to administer the entire single event dose in less than 5 minutes with at least 5 micrograms of treprostinil or a pharmaceutically acceptable salt thereof being inhaled per breath through coordinated actuation of the dry powder inhaler with each breath, and administering to a human suffering from pulmonary hypertension with the dry powder inhaler the single event dose comprising at least 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof in 1 to 3 breaths, wherein the human administers the entire single event dose with the dry powder inhaler in less than 5 minutes by inhaling at least 5 micrograms of treprostinil or a pharmaceutically acceptable salt thereof per breath by coordinating one actuation of the dry powder inhaler for each separate breath, and wherein administration of an additional single event dose in the same manner occurs at least 3 hours later. 2. The method of claim 1, further comprising administering at least 3 hours later an additional single event dose comprising at least 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof in 1 to 3 breaths, wherein the human administers the entire single event dose with the inhalation device in less than 5 minutes by inhaling at least 5 micrograms of treprostinil or a pharmaceutically acceptable salt thereof per breath by coordinating one actuation of the dry powder inhaler for each separate breath. 3. The method of claim 1, wherein the human administers the single event dose several times per day. 4. The method of claim 1, wherein the powder formulation comprises particles less than 5 micrometers in diameter. 5. The method of claim 1, wherein the powder formulation contains no metacresol. 6. The method of claim 1, wherein the human inhales each single event dose in less than about 1 minute. 7. The method of claim 1, wherein the dry powder inhaler is configured to administer at least 15 micrograms of treprostinil or its pharmaceutically effective salt per breath and the human inhales at least 15 micrograms of treprostinil or a pharmaceutically acceptable salt thereof per breath by coordinating one actuation of the dry powder inhaler for each separate breath. 8. The method of claim 1, wherein the single event dose provides a maximal treprostinil plasma concentration in the human of at least 0.65±0.28 ng/ml. 9. The method of claim 1, wherein the single event dose provides a peak plasma concentration of treprostinil in the human at about 10-15 minutes after inhalation. 10. The method of claim 1, wherein the single event dose comprises from 15 micrograms to 90 micrograms of treprostinil or a pharmaceutically acceptable salt thereof. 11. The method of claim 6, wherein the time between breaths is about 6 seconds. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
